Rani Therapeutics Holdings, Inc. (RANI) is a Biotechnology company in the Healthcare sector, currently trading at $0.96. It has a SharesGrow Score of 56/100, indicating a above average investment profile with 3 out of 7 criteria passed.
Analyst consensus target is RANI = $16 (+1532.3% upside).
Valuation: RANI trades at a trailing Price-to-Earnings (P/E) of -3.9 (S&P 500 average ~25) with a forward Price/Earnings-to-Growth (PEG) of 0.46.
Financials: revenue is $2M, +58.9%/yr average growth. Net income is $30M (loss), growing at +19.7%/yr. Net profit margin is -1817.1% (negative). Gross margin is 44.9% (-55.1 pp trend).
Balance sheet: total debt is $4M against $33M equity (Debt-to-Equity (D/E) ratio 0.13, conservative). Current ratio is 4.21 (strong liquidity). Debt-to-assets is 7.4%. Total assets: $59M.
Analyst outlook: 7 / 7 analysts rate RANI as buy (100%) — strong consensus.
SharesGrow 7-Criteria breakdown: Value 100/100 (Pass), Growth 90/100 (Pass), Past 0/100 (Fail), Health 67/100 (Partial), Moat 28/100 (Fail), Future 100/100 (Pass), Income 10/100 (Fail).
